A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo

The Smoothened (SMO) receptor is the most druggable target in the Hedgehog (HH) pathway for anticancer compounds. However, SMO antagonists such as vismodegib rapidly develop drug resistance. In this study, new SMO antagonists having the versatile purine ring as a scaffold were designed, synthesised,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zárate, Ana María, Espinosa-Bustos, Christian, Guerrero, Simón, Fierro, Angélica, Oyarzún-Ampuero, Felipe, Quest, Andrew F. G., Di Marcotullio, Lucia, Loricchio, Elena, Caimano, Miriam, Calcaterra, Andrea, González-Quiroz, Matías, Aguirre, Adam, Meléndez, Jaime, Salas, Cristian O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395040/
https://www.ncbi.nlm.nih.gov/pubmed/34445078
http://dx.doi.org/10.3390/ijms22168372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395040/
https://www.ncbi.nlm.nih.gov/pubmed/34445078
http://dx.doi.org/10.3390/ijms22168372

Ejemplares similares